MIST ▲ +5.9% - Milestone Pharmaceuticals Inc. $MIST - Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States Milestone Pharmaceuticals rose 5.9% following news that China's NMPA approved its etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT), marking the company's first regulatory clearance for the drug outside the United States. The approval expands the commercial potential of etripamil beyond the U.S. market where it was previously authorized. 03-SEP-2026 09:35 AM ET